#Sweden #Stockholm #Eisai #Leqembi #BioArctic

Leqembi Iqlik Selected as One of TIME’s Best Inventions of 2025

In an exciting development for the field of healthcare, Leqembi Iqlik—a unique subcutaneous autoinjector formulation designed for the treatment of Alzheimer's disease—has been recognized as one of TIME's 'Best Inventions of 2025.' This selection highlights the innovation and potential impact of this therapy in enhancing patient care and treatment options.

TIME's annual list spotlights extraordinary innovations across various fields that are not only changing lives but also shaping future possibilities. The process of selecting these inventions includes nominations from TIME editors and global correspondents, reviewed based on criteria such as originality, effectiveness, ambition, and broader societal impact. Among many contenders, Leqembi Iqlik stood out, showcasing the importance of innovation in fighting Alzheimer’s and improving the lives of those affected.

Collaboration for a Breakthrough

Leqembi Iqlik is a product of a longstanding partnership between BioArctic AB and Eisai, whose teams worked tirelessly to bring this groundbreaking treatment to fruition. Originally developed by BioArctic, the antibody involved in Leqembi was based on pioneering research conducted by Professor Lars Lannfelt, who discovered the Arctic mutation linked to Alzheimer's disease. While Eisai has taken charge of clinical development and market approvals, BioArctic retains commercialization rights in the Nordic region, setting the stage for joint efforts to advance this therapeutic solution.

As one of the first treatments to effectively slow the progression of Alzheimer's disease, Leqembi Iqlik involves administering a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that targets harmful amyloid-beta proteins in the brain. This innovative approach has gained approvals in 50 countries, including the United States, Japan, and several European nations, for early-stage Alzheimer’s disease patients.

Ongoing Studies and Future Potential

Phase 3 clinical trials of Leqembi are underway, including the AHEAD 3-45 study that focuses on individuals exhibiting preclinical Alzheimer's symptoms. This research aims to deepen our understanding of how early intervention can alter the disease's trajectory. Funded partly by the National Institute on Aging and conducted through a public-private partnership, this study exemplifies a comprehensive approach to Alzheimer’s treatment and research.

Furthermore, BioArctic is also developing other therapeutics targeting neurodegenerative diseases—expanding its research base to include conditions such as Parkinson's and ALS, utilizing novel technologies like the BrainTransporter™ system aimed at overcoming challenges in delivering therapies across the blood-brain barrier.

The Future of Alzheimer’s Treatment

The recognition by TIME underscores the potential of Leqembi Iqlik to not only change the landscape of Alzheimer’s treatments but also to inform future innovations in the field of neurodegenerative diseases. With advancing clinical studies and partnerships shaping the research landscape, both BioArctic and Eisai are preparing for commercial launch efforts, hoping to reach patients who need these advancements the most.

For further updates and extensive details about Leqembi Iqlik’s journey and its impact on Alzheimer's treatment, visit the official BioArctic website. As research in this area continues to evolve, there’s a collective hope that therapies like Leqembi will transform lives and provide much-needed relief to those affected by Alzheimer’s disease.

This innovative approach has indeed paved the way for future breakthroughs, as BioArctic and Eisai persistently pursue their mission of pioneering effective treatments for those battling neurodegenerative challenges.